Science1 min read

STAT+: Tango reports 82% tumor response rate in trial of combo therapy for advanced pancreatic cancer

By · Via STAT Health · Published by Everything Blog

In short

Tango Therapeutics and Revolution Medicines report a 82% tumor response rate in patients with advanced pancreatic cancer following a combination therapy regimen, which includes an experimental drug from Tango and Rasonque. This regimen, free from chemotherapy, led to 88% of patients remaining free of tumor progression at nine months, supporting the theory of combining targeted drugs for better outcomes in pancreatic cancer. The article is exclusive to STAT+ subscribers.

Key points

  • STAT+ subscribers can access the full article and daily coverage and analysis of the biot…: STAT+ subscribers can access the full article and daily coverage and analysis of the biotech sector.
  • This data supports the theory that combinations of targeted drugs can provide greater ben…: This data supports the theory that combinations of targeted drugs can provide greater benefit for pancreatic cancer patients compared to single drugs.

Sources checked by our analysis pipeline: 1

MADRID — The combination of an experimental drug from Tango Therapeutics and Revolution Medicines’ Rasonque led to tumor responses in 82% of patients with a certain type of advanced pancreatic cancer, clinical trial results reported Friday showed.

The responses were also durable: 88% of the patients were still alive without tumor progression when assessed at nine months.

The new data bolster the theory that patients with pancreatic cancer can derive more benefit from combinations of targeted drugs than single drugs. The Tango regimen is also notable for the absence of chemotherapy, long considered a standard treatment for the aggressive cancer.

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Original source: www.statnews.com

Science